MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 (Xervyteg®) in Acute GvHD at ASH 2025 Annual Congress and…
Categorie
Xervyteg
MaaT Pharma Announces Positive Phase 3 Results Evaluating Xervyteg® (MaaT013) in Acute Graft-versus-Host Disease Selected for Oral Presentation at ASH…
November 3, 2025
MaaT Pharma Publishes its Half Year 2025 Results and Provides a Business Update Positive results from Phase 3 trial for…
September 17, 2025
MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg® in acute Graft-versus Host Disease in Europe MaaT Pharma and…
July 2, 2025
MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025 Marketing Authorization application of Xervyteg® (MaaT013) in…
June 19, 2025
MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg® at the EHA Congress Validating High Efficacy Observed…
June 13, 2025
We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.
Ressources
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.